Ranbaxy Laboratories Limited

218 articles about Ranbaxy Laboratories Limited

• Core Team At Ranbaxy Laboratories U.S. Unit Resigned: Report

  10/15/2014

• Ranbaxy Laboratories Launches ABSORICA® (isotretinoin) 25 Mg And 35 Mg Capsules In The U.S. Market

  10/1/2014

• More Exits From Ranbaxy Laboratories' Top Management Team

  8/21/2014

• Management Reshuffle At Ranbaxy Laboratories: Arno Gessner Promoted, New R&D Head Named

  7/28/2014

• Cipher Pharmaceuticals And Ranbaxy Laboratories Announce Distribution Agreement For Isotretinoin Product In Brazil

  7/24/2014

• India's Ranbaxy Laboratories Wins FDA Approval For Novartis AG's Diovan Generic

  6/27/2014

• Europeans, U.S. Disagree Over Safety Of Ranbaxy Laboratories Facility

  6/6/2014

• Ranbaxy Laboratories Purchases Instem’s Preclinical Software Suite

  5/8/2014

• Ranbaxy Laboratories Recalls Nearly 30,000 Packs Of Allergy-Relief Drug In U.S.

  5/6/2014

• Sun Pharmaceutical Industries Ltd, Ranbaxy Laboratories Merger Equals Generic Powerhouse: Layoffs Projected To Save $250 Million In Costs

  4/14/2014

• Job Cut Worries For Ranbaxy Laboratories' Sales Team

  4/10/2014

• Sun Pharmaceutical Industries Ltd Plans To Gradually Phase-Out Of Ranbaxy Laboratories-Branded Drugs In U.S.

  4/9/2014

• Sun Pharmaceutical Industries Ltd To Buy Struggling Ranbaxy Laboratories In $3.2-Billion Landmark Transaction

  4/7/2014

• Ranbaxy Laboratories Scrambles For Ingredients To Make Generic Nexium

  3/11/2014

• More Trouble As Ranbaxy Laboratories Recalls More Than 60,000 Bottles Of Generic Lipitor In U.S.

  3/11/2014

• Ranbaxy Laboratories, Teva Pharmaceutical Industries Limited Settle Claims In U.S. Over Collusion

  2/19/2014

• Daiichi Sankyo, Inc. Pledges Bold Action On Ranbaxy Laboratories Production Problems

  1/31/2014

• Ranbaxy Laboratories Workers Fudged Test Results: FDA

  1/28/2014

• Ranbaxy Laboratories Drops A Little More As The FDA Bans More Products

  1/24/2014

• Ranbaxy Laboratories In Tie-Up For Generic Of Novartis AG's Diovan, If Approved, Ranbaxy Could Grab 50 Percent Of Its $1.5 Billion Market

  1/17/2014